Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre Study to Determine the Efficacy and Dose Response of Repeat Inhaled Doses of GW870086X on FEV1 in Adults With Persistent Asthma

NCT01245426 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01245426
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01245426 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre Study to Determine the Efficacy and Dose Response of Repeat Inhaled Doses of GW870086X on FEV1 in Adults With Persistent Asthma
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2010
Completion date
August 31, 2011
Enrollment
136 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

asthma